Slappendel R J, Teske E
Department of Clinical Sciences of Companion Animals, University of Utrecht, The Netherlands.
Vet Q. 1997 Mar;19(1):10-3. doi: 10.1080/01652176.1997.9694729.
The efficacy of i.v. versus s.c. administration of Glucantime (100 mg/kg of body weight/day) was studied in 41 dogs with leishmaniasis without serious renal insufficiency. Remission was obtained in 35 dogs (85.4%) after 3 to 6 weeks of treatment but there was a relapse within 1 year in 26 dogs (74.3%). The median period of remission was 6 months. Cross-over therapy resulted in remission in 17 of 20 dogs. The percentage of remission after initial and cross-over therapy, the median relapse free period, and survival did not differ significantly between the two groups. There were very few complications and most were of minor clinical importance. Thrombophlebitis developed in one dog after i.v. injection. In dogs with leishmaniasis without serious renal insufficiency, there is a 75% probability of survival for more than 4 years following treatment with Glucantime for 3 to 6 weeks, with additional treatment when relapses occur.
在41只无严重肾功能不全的利什曼病犬中，研究了静脉注射与皮下注射葡糖胺锑钠（100mg/kg体重/天）的疗效。治疗3至6周后，35只犬（85.4%）病情缓解，但26只犬（74.3%）在1年内复发。缓解的中位期为6个月。交叉治疗使20只犬中的17只病情缓解。两组在初始治疗和交叉治疗后的缓解率、无复发中位期和生存率无显著差异。并发症很少，且大多临床意义不大。静脉注射后1只犬发生血栓性静脉炎。在无严重肾功能不全的利什曼病犬中，用葡糖胺锑钠治疗3至6周后，有75%的概率存活超过4年，复发时进行额外治疗。
